256 filings
8-K
MTNB
Matinas Biopharma Holdings Inc
9 May 24
Matinas BioPharma Reports First Quarter 2024 Financial Results and Provides a Business Update
4:06pm
8-K
MTNB
Matinas Biopharma Holdings Inc
5 Apr 24
Matinas BioPharma Announces Registered Direct Offering of $10 Million
7:00am
424B5
MTNB
Matinas Biopharma Holdings Inc
4 Apr 24
Prospectus supplement for primary offering
4:15pm
8-K
MTNB
Matinas Biopharma Holdings Inc
28 Mar 24
Regulation FD Disclosure
9:00am
8-K
l3pcu2 bohk4sxhfbg4v
27 Mar 24
Matinas BioPharma Reports 2023 Financial Results and Provides a Business Update
4:22pm
8-K
26ebdhlt
25 Mar 24
Matinas BioPharma Announces Positive in vivo Safety Data with its Oral LNC-Docetaxel Formulation
8:05am
8-K
hnmk8lyjto2wsokio0fy
22 Mar 24
Regulation FD Disclosure
9:20am
8-K
gfzdypdcufwbosvn7l
22 Mar 24
Other Events
6:35am
8-K
q31u lmcg34
26 Feb 24
Regulation FD Disclosure
8:05am
8-K
fm9g znjg
20 Feb 24
Regulation FD Disclosure
7:35am
8-K
swi0cmti
9 Jan 24
Regulation FD Disclosure
7:30am
8-K
0zl9i9z5 901dsf
27 Dec 23
In an acute psoriasis model, data show reductions in tissue IL-17A mRNA and improvement in clinical disease markers including skin lesions
7:40am
8-K
sqdpp542pu2xpx83o
21 Dec 23
Matinas BioPharma Provides Update to MAT2203 Regulatory and Development Pathway Following Feedback from FDA
7:40am
8-K
6vhjiz
20 Nov 23
Regulation FD Disclosure
7:30am
8-K
wciy6zhm3phso1cx8q7
9 Nov 23
Matinas BioPharma Announces Positive in vivo Efficacy Results of Oral LNC Docetaxel Formulation in a Melanoma Model
5:25pm
8-K
m2ky1k
8 Nov 23
Matinas BioPharma Reports Third Quarter 2023 Financial Results and Provides a Business Update
4:06pm
8-K
3j1zl
2 Nov 23
Submission of Matters to a Vote of Security Holders
5:20pm